

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/020615-2023>

Award

Community Hydroxychloroquine and Chloroquine Monitoring Service - Bradford District and Craven Health and Care Partnership

NHS West Yorkshire Integrated Care Board

F15: Voluntary ex ante transparency notice

Notice identifier: 2023/S 000-020615

Procurement identifier (OCID): ocds-h6vhtk-03e2e5

Published 18 July 2023, 11:27am

Section I: Contracting authority/entity

I.1) Name and addresses

NHS West Yorkshire Integrated Care Board

White Rose House

Wakefield

WF1 1LT

Contact

Chris Balson

Email

wycb-kirk.procurement@nhs.net

Country

United Kingdom

Region code

UK - United Kingdom

Internet address(es)

Main address

<https://www.wypartnership.co.uk/>

I.4) Type of the contracting authority

Body governed by public law

I.5) Main activity

Health

Section II: Object**II.1) Scope of the procurement****II.1.1) Title**

Community Hydroxychloroquine and Chloroquine Monitoring Service - Bradford District and Craven Health and Care Partnership

II.1.2) Main CPV code

- 85100000 - Health services

II.1.3) Type of contract

Services

II.1.4) Short description

A community service that provides routine monitoring of patients on Hydroxychloroquine (HCQ) as per the guidelines and recommendations of the Royal College of Ophthalmologists (Hydroxychloroquine Retinopathy Monitoring Guideline). however currently there is no service provision with BD&C HCP

We have worked with a community provider, Shipley Ophthalmic Assessment Programme (SOAP), to create a monitoring provision to bridge this gap.

II.1.6) Information about lots

This contract is divided into lots: No

II.1.7) Total value of the procurement (excluding VAT)

Value excluding VAT: £75,615

II.2) Description

II.2.3) Place of performance

NUTS codes

- UKE - Yorkshire and the Humber

II.2.4) Description of the procurement

A community service that provides routine monitoring of patients on Hydroxychloroquine (HCQ) as per the guidelines and recommendations of the Royal College of Ophthalmologists (Hydroxychloroquine Retinopathy Monitoring Guideline).

II.2.11) Information about options

Options: No

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

Section IV. Procedure

IV.1) Description

IV.1.1) Type of procedure

Award of a contract without prior publication of a call for competition in the cases listed below

- The procurement falls outside the scope of application of the regulations

Explanation:

Routine monitoring of patients on Hydroxychloroquine (HCQ) is as per the guidelines and

recommendations of the Royal College of Ophthalmologists (Hydroxychloroquine Retinopathy Monitoring Guideline), however currently there is no service provision with BD&C HCP.

We have worked with a community provider, Shipley Ophthalmic Assessment Programme (SOAP), to create a monitoring provision to bridge this gap.

HCQ is a medicine that is effective in treating various long-term inflammatory disorders of the joints and skin (usually prescribed in rheumatology/dermatology). In general, it is a safe and cost-effective medication, particularly when compared to newer anti-inflammatory medicines which can more significant adverse effects on the body. However, some patients taking hydroxychloroquine, or a similar medication called chloroquine, can suffer permanent loss of vision due to retinopathy.

As a result of this, once prescribed the guidelines recommend that a baseline is taken of a patient's eye health, and dependent upon some other factors, once a patient has been on this drug for 5 years they should begin routine annual monitoring to ensure that the retina is maintaining health.

The monitoring of these patients has not been undertaken in BD&C HCP, with Hospital Eye Services (HES) unable to take on the burden of these patients from either a capacity (HES services were and are already overflowing), or capability (lack of further clinic space).

WY colleagues are now raising the risk index on this matter as they now believe we have patients who have been unmonitored on HCQ for 7 years or slightly greater (2 years beyond the guidelines for routine monitoring), although they are working with Meds Mgt teams to accurately identify the specific cohort and the number of patients involved.

Justification under which formal quotation/tendering process is to be waived:

(g) where specialist expertise/service/works/goods are required, and these are available from only one source (specialised service).

IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes

Section V. Award of contract/concession

Contract No

1

A contract/lot is awarded: Yes

V.2) Award of contract/concession

V.2.1) Date of conclusion of the contract

1 March 2023

V.2.2) Information about tenders

The contract has been awarded to a group of economic operators: No

V.2.3) Name and address of the contractor/concessionaire

The Saltaire & Windhill Medical Partnership

Cliffe Avenue

Shipley

BD17 6NX

Country

United Kingdom

NUTS code

- UKE - Yorkshire and the Humber

The contractor/concessionaire is an SME

Yes

V.2.4) Information on value of contract/lot/concession (excluding VAT)

Total value of the contract/lot/concession: £75,615

V.2.5) Information about subcontracting

The contract/lot/concession is likely to be subcontracted

Section VI. Complementary information

VI.4) Procedures for review

VI.4.1) Review body

Royal Court of Justice

Strand, Holborn

London

WC2A 2LL

Country

United Kingdom

Internet address

<https://courtribunalfinder.service.gov.uk/courts/royal-courts-of-justice>